# A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

> **NCT04700280** · PHASE2 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 31 (actual)

## Conditions studied

- Primary Sjögren Syndrome

## Interventions

- **DRUG:** GLPG3970
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04700280
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-28
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-12-27
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study was terminated based on Sponsor decision
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700280, "A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04700280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*